| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.PCAN.4500561 |
| P698 | PubMed publication ID | 12496995 |
| P2093 | author name string | Kyprianou N | |
| Glassman DT | |||
| Anglin IE | |||
| P2860 | cites work | SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor | Q22008583 |
| Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes | Q24310852 | ||
| The NF-kappa B and I kappa B proteins: new discoveries and insights | Q24313579 | ||
| Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. | Q24540358 | ||
| Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor | Q24631156 | ||
| Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis | Q28139074 | ||
| TGFbeta signaling in growth control, cancer, and heritable disorders | Q28142605 | ||
| Role of transforming growth factor-beta signaling in cancer | Q28145449 | ||
| Mechanism of activation of the TGF-beta receptor | Q28245861 | ||
| Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt | Q28255373 | ||
| Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia | Q28376281 | ||
| Function and activation of NF-kappa B in the immune system | Q29547790 | ||
| How cells read TGF-beta signals | Q29619993 | ||
| 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity | Q30658242 | ||
| Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia | Q31912887 | ||
| How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex | Q33797139 | ||
| Cancer statistics, 2000. | Q33895772 | ||
| Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target | Q33992373 | ||
| A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras | Q35193411 | ||
| The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome | Q38305593 | ||
| Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells | Q38326377 | ||
| Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate-Specific Antigen—Based Screening | Q39377765 | ||
| Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. | Q39377886 | ||
| Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells | Q39441132 | ||
| Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension | Q39469038 | ||
| Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells | Q40444996 | ||
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma | Q41261975 | ||
| Prostatic alpha 1-adrenoceptors and uroselectivity | Q41448071 | ||
| A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
| Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase | Q41639273 | ||
| Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues | Q42450073 | ||
| Expression of androgen receptor and growth factors in premalignant lesions of the prostate | Q42467183 | ||
| Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression | Q42526531 | ||
| Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin | Q43658895 | ||
| Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck | Q45263082 | ||
| Doxazosin: a new cytotoxic agent for prostate cancer? | Q50512920 | ||
| Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. | Q50770321 | ||
| Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. | Q50778379 | ||
| Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. | Q52527064 | ||
| Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. | Q54637719 | ||
| Epidermal Growth Factor Impairs the Cytochrome C/Caspase-3 Apoptotic Pathway Induced by Transforming Growth Factorβ in Rat Fetal Hepatocytes Via a Phosphoinositide 3-Kinase–Dependent Pathway | Q59602439 | ||
| Alpha1-adrenoceptor subtypes in the human prostate | Q61614220 | ||
| Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells | Q68617970 | ||
| Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death | Q69419588 | ||
| Activation of programmed cell death in the rat ventral prostate after castration | Q69816264 | ||
| Pharmacokinetics of terazosin | Q69882736 | ||
| Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens | Q69923603 | ||
| Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal gro | Q72019094 | ||
| Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy | Q72081134 | ||
| The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle | Q72219825 | ||
| Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer | Q73404302 | ||
| Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin | Q73868493 | ||
| ErbB kinases and NDF signaling in human prostate cancer cells | Q73945597 | ||
| TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu | Q74070676 | ||
| Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist | Q74605813 | ||
| Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway | Q77463961 | ||
| P433 | issue | 2 | |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 88-95 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Prostate Cancer and Prostatic Diseases | Q2108326 |
| P1476 | title | Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component | |
| P478 | volume | 5 |
| Q95325959 | A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy |
| Q33927817 | Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3. |
| Q36827500 | Advances in the design and synthesis of prazosin derivatives over the last ten years |
| Q34498911 | Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload |
| Q39272532 | Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells |
| Q33746215 | Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment? |
| Q28476183 | Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells |
| Q51464757 | Copper-catalyzed oxidative coupling between quinazoline 3-oxides and unactivated aldehydes: an efficient approach to functionalized quinazolines. |
| Q54615392 | Coupling of α1-adrenoceptors to ERK1/2 in the human prostate. |
| Q42173038 | Evaluation of discoidin domain receptor-2 (DDR2) expression level in normal, benign, and malignant human prostate tissues |
| Q34118150 | Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection |
| Q34791930 | Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia |
| Q38716504 | Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival α1B-Adrenergic Receptors in Human SW480 Colon Carcinoma Cells |
| Q33989019 | Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. |
| Q38551294 | New intraprostatic injectables and prostatic urethral lift for male LUTS. |
| Q33721812 | New treatments for chronic prostatitis/chronic pelvic pain syndrome |
| Q34485602 | Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms |
| Q39064824 | Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth. |
| Q38137877 | Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling |
| Q36648945 | Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction |
| Q38793967 | Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines |
| Q34506119 | Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle |
| Q37111860 | Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses |
| Q26740401 | The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers |
| Q44883128 | The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome |
| Q35784033 | The role of alpha-blockers in the management of prostate cancer |
| Q37929670 | The use of botulinum toxin in benign prostatic hyperplasia |
| Q33746225 | Therapeutic value of quinazoline-based compounds in prostate cancer |
| Q39804158 | Transforming growth factor-beta type I receptor/ALK5 contributes to doxazosin-induced apoptosis in H9C2 cells. |
| Q36181722 | Various treatment options for benign prostatic hyperplasia: A current update |
| Q83274848 | β-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors |
Search more.